Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children Aged 6-12 With a Diagnosis of Attention-Deficit/Hyperactivity Disorder

NCT00997984 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00997984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00997984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children Aged 6-12 With a Diagnosis of Attention-Deficit/Hyperactivity Disorder
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
November 17, 2009
Completion date
October 9, 2010
Enrollment
340 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

attention-deficit/hyperactivity disorder